These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 8733770

  • 1. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
    Gorgoulis VG, Rassidakis GZ, Karameris AM, Papastamatiou H, Trigidou R, Veslemes M, Rassidakis AN, Kittas C.
    Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
    [Abstract] [Full Text] [Related]

  • 2. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA, Huang L, Berger D, Chang H, Klein-Szanto AJ, Goodrow T, Wood M, Obara T, Heath CW, Lynch H.
    Cancer; 1997 Feb 15; 79(4):700-16. PubMed ID: 9024708
    [Abstract] [Full Text] [Related]

  • 3. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma.
    Gorgoulis VG, Zoumpourlis V, Rassidakis GZ, Karameris A, Rassidakis AN, Spandidos DA, Kittas C.
    J Pathol; 1996 Oct 15; 180(2):129-37. PubMed ID: 8976869
    [Abstract] [Full Text] [Related]

  • 4. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation.
    Pruneri G, Pignataro L, Carboni N, Luminari S, Capaccio P, Neri A, Buffa R.
    Mod Pathol; 1997 Aug 15; 10(8):785-92. PubMed ID: 9267820
    [Abstract] [Full Text] [Related]

  • 5. [The expression of Mdm2 protein and p53 mutation in lung squamous cell carcinomas and their clinicopathological significance].
    Zhang J, Liu H, Li S, Gu C.
    Zhonghua Jie He He Hu Xi Za Zhi; 1999 Mar 15; 22(3):163-5. PubMed ID: 11812371
    [Abstract] [Full Text] [Related]

  • 6. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
    Irie K, Ishida H, Furukawa T, Koyanagi K, Miyamoto Y.
    Rinsho Byori; 1996 Jan 15; 44(1):32-41. PubMed ID: 8691638
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
    Osman I, Scher HI, Zhang ZF, Pellicer I, Hamza R, Eissa S, Khaled H, Cordon-Cardo C.
    Clin Cancer Res; 1997 Apr 15; 3(4):531-6. PubMed ID: 9815716
    [Abstract] [Full Text] [Related]

  • 9. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.
    Mori S, Ito G, Usami N, Yoshioka H, Ueda Y, Kodama Y, Takahashi M, Fong KM, Shimokata K, Sekido Y.
    Cancer; 2004 Apr 15; 100(8):1673-82. PubMed ID: 15073856
    [Abstract] [Full Text] [Related]

  • 10. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
    Bánkfalvi A, Tory K, Kemper M, Breukelmann D, Cubick C, Poremba C, Füzesi L, Lellè RJ, Böcker W.
    Pathol Res Pract; 2000 Apr 15; 196(7):489-501. PubMed ID: 10926327
    [Abstract] [Full Text] [Related]

  • 11. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression.
    Poremba C, Yandell DW, Metze D, Kamanabrou D, Böcker W, Dockhorn-Dworniczak B.
    Oncol Res; 1995 Apr 15; 7(7-8):331-9. PubMed ID: 8747596
    [Abstract] [Full Text] [Related]

  • 12. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer.
    Mizera-Nyczak E, Dyszkiewicz W, Heider KH, Zeromski J.
    Tumour Biol; 2001 Apr 15; 22(1):45-53. PubMed ID: 11054026
    [Abstract] [Full Text] [Related]

  • 13. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
    Shwe M, Chiguchi G, Yamada S, Nakajima T, Maung KK, Takagi M, Amagasa T, Tsuchida N.
    J Med Dent Sci; 2001 Dec 15; 48(4):113-9. PubMed ID: 12160248
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia.
    Dellas A, Schultheiss E, Almendral AC, Gudat F, Oberholzer M, Feichter G, Moch H, Torhorst J.
    Int J Cancer; 1997 Aug 22; 74(4):421-5. PubMed ID: 9291432
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.
    Koga T, Hashimoto S, Sugio K, Yoshino I, Nakagawa K, Yonemitsu Y, Sugimachi K, Sueishi K.
    Int J Cancer; 2001 Jul 20; 95(4):232-9. PubMed ID: 11400116
    [Abstract] [Full Text] [Related]

  • 18. Abnormal expression of MDM2 in prostate carcinoma.
    Leite KR, Franco MF, Srougi M, Nesrallah LJ, Nesrallah A, Bevilacqua RG, Darini E, Carvalho CM, Meirelles MI, Santana I, Camara-Lopes LH.
    Mod Pathol; 2001 May 20; 14(5):428-36. PubMed ID: 11353053
    [Abstract] [Full Text] [Related]

  • 19. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
    Belinsky SA, Middleton SK, Picksley SM, Hahn FF, Nikula KJ.
    Radiat Res; 1996 Apr 20; 145(4):449-56. PubMed ID: 8600505
    [Abstract] [Full Text] [Related]

  • 20. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations.
    Günther T, Schneider-Stock R, Häckel C, Kasper HU, Pross M, Hackelsberger A, Lippert H, Roessner A.
    Mod Pathol; 2000 Jun 20; 13(6):621-6. PubMed ID: 10874665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.